Ursodeoxycholic Acid Market Report 2026

Ursodeoxycholic Acid Market Overview

• Ursodeoxycholic Acid market size has reached to $0.96 billion in 2025 • Expected to grow to $1.6 billion in 2030 at a compound annual growth rate (CAGR) of 10.7% • Growth Driver: Rising Prevalence Of Liver Diseases Driving The Growth Of The Market Due To Increasing Alcohol Consumption And Associated Liver Conditions • Market Trend: New Therapy Aims To Improve Liver Function And Slow Damage • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Ursodeoxycholic Acid Market?

Ursodeoxycholic acid (UDCA) is a bile acid naturally produced in small amounts by the human liver and is used as a medication to dissolve certain types of gallstones and to treat certain liver and gallbladder diseases. It helps dissolve cholesterol gallstones and improves bile flow, protecting liver cells from damage. Ursodeoxycholic acid is considered a safe and effective therapy for managing cholestatic liver disorders. The main types of ursodeoxycholic acid are synthetic ursodeoxycholic acid and extraction ursodeoxycholic acid. Synthetic ursodeoxycholic acid refers to a man-made version of a natural bile acid used to treat liver disorders and dissolve cholesterol gallstones by improving bile flow and reducing liver cell damage. It can be administered orally, intravenously, or subcutaneously and is primarily used to treat gallstones, primary biliary cholangitis, primary sclerosing cholangitis, non-alcoholic fatty liver disease, and other liver and biliary conditions. It is distributed through hospital, retail, and online pharmacies, catering to end users such as hospitals, specialty clinics, research institutions, and others.

What Is The Ursodeoxycholic Acid Market Growth Forecast?

The ursodeoxycholic acid market size is expected to see rapid growth in the next few years. It will grow to $1.6 billion in 2030 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to advancements in chemical and enzymatic synthesis, rising prevalence of liver and biliary diseases, expansion of specialty clinics and research institutions, increased regulatory approvals for synthetic udca, development of novel administration formulations. Major trends in the forecast period include rising prevalence of gallstones and cholestatic liver disorders, increased adoption of synthetic and biosynthetic udca, expansion of oral and intravenous administration routes, growing use in research and clinical trials for liver diseases, focus on personalized treatment and dosage optimization.

Global Ursodeoxycholic Acid Market Segmentation

1) By Type: Synthetic Ursodeoxycholic Acid, Extraction Ursodeoxycholic Acid 2) By Route Of Administration: Oral, Intravenous, Subcutaneous 3) By Application: Gallstones, Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Non-Alcoholic Fatty Liver Disease, Other Liver And Biliary Diseases 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels 5) By End User: Hospitals, Specialty Clinics, Research Institutions, Other End Users Subsegments: 1) By Synthetic Ursodeoxycholic Acid: Chemically Synthesized Ursodeoxycholic Acid, Biosynthetic Ursodeoxycholic Acid, Enzymatically Synthesized Ursodeoxycholic Acid 2) By Extraction Ursodeoxycholic Acid: Animal-Derived Ursodeoxycholic Acid, Bile Extracted Ursodeoxycholic Acid, Natural Source Extracted Ursodeoxycholic Acid

What Are The Drivers Of The Ursodeoxycholic Acid Market?

The rising prevalence of liver diseases is expected to propel the growth of the ursodeoxycholic acid market going forward. Liver diseases refer to various conditions that impair the liver's ability to function properly, including infections, inflammation, fatty liver, cirrhosis, and liver cancer. The rising prevalence of liver diseases is due to increasing alcohol consumption, as excessive drinking over time can lead to damage of the liver. Ursodeoxycholic acid supports liver disease treatment by improving bile flow and reducing toxic bile acids, making it effective for conditions such as primary biliary cholangitis. It enhances patient outcomes by slowing liver damage progression and aiding in cholesterol gallstone dissolution, increasing overall treatment efficiency. For instance, in April 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, there were 6,664 premature deaths from liver disease among males and 3,929 among females, marking a 22.8% increase for males and a 33.1% increase for females compared to 2023. Therefore, the rising prevalence of liver diseases is driving the growth of the ursodeoxycholic acid industry. The rising aging population is expected to propel the growth of the ursodeoxycholic acid market in the coming years. The term 'aging population' refers to the increasing percentage and proportion of elderly people in the population. The world's economy, healthcare systems, and social support networks are all affected by the aging population. Older people are more likely to develop osteoporosis, which necessitates early identification and prevention, the importance of bone health, and its influence on healthcare. Ursodeoxycholic acid is used in aging populations to support liver function by treating cholestatic liver diseases and improving bile flow. For instance, in January 2024, according to a published Pew Research Center, a US-based organization, 101,000 in 2024. The aging population increases up to 420,000 in 2054. Therefore, the rising aging population is driving the ursodeoxycholic acid industry.

Key Players In The Global Ursodeoxycholic Acid Market

Major companies operating in the ursodeoxycholic acid market are Mankind Pharma Pvt. Ltd, Abbott Healthcare Pvt. Ltd., Shandong Octagon Chemicals Limited, J.S.C. Grindeks, Arch Pharmalabs, Ind Swift Laboratories Ltd., Symbiotec Pharmalab, Suzhou Tianlu Bio-pharmaceutical Co. Ltd, Zeal MediPharma, Prodotti Chimici e Alimentari S.P.A., Mitsubishi Tanabe Pharma Corporation, ICE Pharma Inc, Xi'an Tian Guangyuan Biotech Co. Ltd, Aamorb Pharmaceuticals Inc., Axplora Inc, Octavius Pharma Pvt. Ltd, Sichuan Elixir Pharmaceutical Co. Ltd, Signova Pharma Pvt. Ltd., Sinoway Industrial Co. Ltd, Valence Labs Pvt. Ltd.

Global Ursodeoxycholic Acid Market Trends and Insights

Major companies operating in the ursodeoxycholic acid (UDCA) market are focusing on developing innovative therapies, such as bile acid derivatives, to enhance the treatment of liver diseases, particularly cholestatic liver disorders. Bile acid derivatives refer to modified forms of bile acids that are used in medical treatments to improve liver function and manage liver diseases. For instance, in November 2024, Nora Pharma Inc., a Canada-based pharmaceutical company, launched a generic version of Ursodiol (ursodeoxycholic acid) for the treatment of cholestatic liver diseases, including primary biliary cholangitis (PBC). This medication is primarily used to enhance liver function and slow the progression of liver damage, particularly when initiated early in the disease. It also aids in dissolving and preventing cholesterol gallstones by modifying bile composition and decreasing toxic bile acids.

Regional Insights

North America was the largest region in the ursodeoxycholic acid market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Ursodeoxycholic Acid Market?

The ursodeoxycholic acid market consists of sales of ursodiol tablets, ursodeoxycholic acid capsules, suspensions, injectables, and combination drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Ursodeoxycholic Acid Market Report 2026?

The ursodeoxycholic acid market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the ursodeoxycholic acid industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.